Page 8 - அமெரிக்கன் சமூகம் க்கு மருத்துவ புற்றுநோயியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Palm Beach, FL –February 23, 2021 – In the breast cancer therapy market, the rise in the prevalence of cancer, has propelled the T-cell therapy market over the last few years and it is projected to continue to do so for several years to come. T-cell therapy includes using genetically engineered T-cells to produce an artificial T-cell receptor for applications in immunotherapy. Growing prevalence of cancer across the world and increase in cancer research & development drive the market. According to the WHO, the number of global cancer deaths is projected to increase by 45% between 2008 and 2030. It is also estimated that by 2030, approximately 10 to 11 million cases of cancers would be diagnosed each year in low- and middle-income countries. The increase in investment in adoptive T-cell transfer approaches of disease treatment drives and the increasing number of clinical trials the market. Furthermore, technological advancements in manufacturing processes and developments in CAR

United statesMatt coffeyMyron holubiakBlanver farmoquVaccinex activmabPatrickj mahaffyErnest smithOncolytics biotech incClovis oncology incAmerican society for clinical oncologyBiotechnology corporationFn media groupMscs programVaccinex incAlliance for clinical trials in oncologyCitius pharmaceuticals